72 related articles for article (PubMed ID: 8073816)
41. Suppression of mitogen-induced lymphoproliferation by soluble IgG Fc receptors in retroplacental serum in normal human pregnancy.
Aarli A; Skeie Jensen T; Ulvestad E; Matre R
Scand J Immunol; 1993 Feb; 37(2):237-43. PubMed ID: 8434234
[TBL] [Abstract][Full Text] [Related]
42. Impaired function of numerically augmented Fc-receptors on granulocytes in a HLA B8+ patient with palmoplantar pustulosis.
Schopf RE; Rehder M; Benes P; Bork K; Morsches B
Arch Dermatol Res; 1987; 279(7):444-8. PubMed ID: 3435172
[TBL] [Abstract][Full Text] [Related]
43. The effect of Goeckerman therapy on interferon in serum and suction blister fluid from patients with psoriasis.
Livden JK; Bjerke JR; Degre M; Matre R
Br J Dermatol; 1986 Feb; 114(2):217-25. PubMed ID: 2418865
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of interferons and TNF-alpha are not correlated to psoriasis activity and therapy.
Tigalonova M; Bjerke JR; Gallati H; Degré M; Jablonska S; Majewski S; Matre R
Acta Derm Venereol Suppl (Stockh); 1994; 186():25-7. PubMed ID: 8073829
[TBL] [Abstract][Full Text] [Related]
45. Intermediate molecular weight substances in sera of psoriatic patients.
Felmérai I; Gróf J; Idei M; Menyhárt J
Acta Physiol Acad Sci Hung; 1982; 60(3):135-8. PubMed ID: 7185254
[TBL] [Abstract][Full Text] [Related]
46. Tenascin-C is not a useful marker for disease activity in psoriasis.
Latijnhouwers MA; Bergers M; Kuijpers AL; van der Vleuten CJ; Dijkman H; van de Kerkhof PC; Schalkwijk J
Acta Derm Venereol; 1998 Sep; 78(5):331-4. PubMed ID: 9779247
[TBL] [Abstract][Full Text] [Related]
47. Ultrastructural features of Langerhans cells in clinically uninvolved skin of psoriatics.
Klug H; Sönnichsen N
J Cutan Pathol; 1988 Dec; 15(6):363-6. PubMed ID: 3065370
[TBL] [Abstract][Full Text] [Related]
48. The acid number of the lipids on the intact and the stripped skin surface in psoriatics.
HERRMANN F; SCHER R; COON WM; MANDOL L
J Invest Dermatol; 1960 Jul; 35():47-56. PubMed ID: 14401359
[No Abstract] [Full Text] [Related]
49. [Serotonin levels in patients with neurodermatitis and psoriasis].
Grebennikov VA; Telegina SA
Vestn Dermatol Venerol; 1972 May; 46(5):31-5. PubMed ID: 5047546
[No Abstract] [Full Text] [Related]
50. Biochemical studies on enzyme activities and substrate concentrations in serum and scales of normal subjects and psoriatics.
Peters G; Schubert E; Peter R
Biochem Med; 1975 Mar; 12(3):242-57. PubMed ID: 1137585
[No Abstract] [Full Text] [Related]
51. Substance-P immunoreactivity in active edges of psoriatic plaques.
Kürkçüoğlu N; Cakar N
Clin Exp Dermatol; 1990 Nov; 15(6):467. PubMed ID: 1703934
[No Abstract] [Full Text] [Related]
52. Nerve growth factor is increased in psoriatic skin.
Fantini F; Magnoni C; Bracci-Laudiero L; Pincelli C TE
J Invest Dermatol; 1995 Dec; 105(6):854-5. PubMed ID: 7490482
[No Abstract] [Full Text] [Related]
53. [Changes in the healthy skin of psoriatics].
Novotný F
Cesk Dermatol; 1966 Jul; 41(3):168-81. PubMed ID: 5329705
[No Abstract] [Full Text] [Related]
54. Studies on the chemical composition of psoriatic scales.
WHEATLEY VR; FARBER EM
J Invest Dermatol; 1961 Mar; 36():199-211. PubMed ID: 13784746
[No Abstract] [Full Text] [Related]
55. [Some blood changes in psoriatics].
LEVY-FRANCKEL A
Ann Dermatol Syphiligr (Paris); 1945; 5():300. PubMed ID: 20982007
[No Abstract] [Full Text] [Related]
56. Survival advantage in CLL with frontline FCR therapy.
O'Brien S
Curr Hematol Malig Rep; 2011 Mar; 6(1):3-4. PubMed ID: 21188558
[No Abstract] [Full Text] [Related]
57. Response to Protocol Review Scenario: FCR and defining the review process.
Jen K; Villano J
Lab Anim (NY); 2017 Mar; 46(4):88-89. PubMed ID: 28328903
[No Abstract] [Full Text] [Related]
58. Fc gamma-receptors in skin and serum from patients with psoriasis, before and after therapy.
Bjerke JR; Tigalonova M; Jensen TS; Matre R
Acta Derm Venereol Suppl (Stockh); 1994; 186():141-2. PubMed ID: 8073816
[TBL] [Abstract][Full Text] [Related]
59. Fc gamma-receptors on Langerhans' cells and keratinocytes in suspension from normal skin characterized using soluble immune complexes and monoclonal antibodies.
Tigalonowa M; Bjerke JR; Matre R
Acta Derm Venereol; 1991; 71(2):99-103. PubMed ID: 1675539
[TBL] [Abstract][Full Text] [Related]
60. Immunological changes following treatment of psoriasis with cyclosporin.
Tigalonowa M; Bjerke JR; Gallati H; Matre R
Acta Derm Venereol Suppl (Stockh); 1989; 146():142-5; discussion 146. PubMed ID: 2481929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
